מכפיל מחיר להכנסות עתידי Citius Oncology Inc. (CTOR)

Citius Oncology, Inc. (CTOR) attracts leading oncologists through generous options to commercialize therapies, reinforcing the brand's status as a valuable niche expert. The projected market capitalization-to-revenue ratio demonstrates valuation dynamics where the 8.60 mark serves as a current indicator. The company is developing an immunotherapy-based cancer combat system by integrating Lymphir into treatment protocols for rare lymphomas.

Citius Oncology, Inc. (CTOR) maintains a stable workforce and retains leading biochemists, creating a foundation for future sales that directly impacts market expectations. By analyzing the company's forward P/S on GURU.Markets, an investor can view the ratio of market capitalization to expected revenue, allowing for an assessment of the asset's premium and the timely balancing of risks through the price action reflected in this chart.